To include your compound in the COVID-19 Resource Center, submit it here.

Intercept raises $400M in debt offering

Hepatic disease company Intercept Pharmaceutics Inc.

Read the full 67 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE